Evidence map›Paper›PMID 19132880›Full record

ArticleJournal of women's health (2002)

Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center.

Adi Cohen, Jessica Fleischer, Matthew J Freeby, Donald J McMahon, Dinaz Irani, Elizabeth Shane

Open access · greenAbstract read
In one paragraph

Article in Journal of women's health (2002). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012
    Pooled it
  2. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.The Journal of clinical endocrinology and metabolism · 2022
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.The Journal of clinical endocrinology and metabolism · 2013
    Trial
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Premenopausal Osteoporosis.Endocrinology and metabolism clinics of North America · 2017
    Review
  12. Article
  13. Article
  14. Review
  15. Increased marrow adiposity in premenopausal women with idiopathic osteoporosis.The Journal of clinical endocrinology and metabolism · 2012
    Article
  16. The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2011
    Article
  17. Bone disease in HIV infection: a practical review and recommendations for HIV care providers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Adi CohenDivision of Endocrinology, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA. ac1044@columbia.edu
Jessica Fleischer
Matthew J Freeby
Donald J McMahon
Dinaz Irani
Elizabeth Shane
Columbia University · US

Funding

IDIOPATHIC OSTEOPOROSIS IN PREMENOPAUSAL WOMENR01AR049896 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHANE, ELIZABETH J · 2005 to 2009
$2.8M
Bone Quality in Premenopausal Women with Idiopathic Fragility FracturesK23AR054127 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI COHEN, ADI · 2007 to 2011
$642k
NIAMS NIH HHS K23 AR054127NIAMS NIH HHS R01 AR049896
6 · The paper itself

Abstract

aimsOsteoporosis is uncommon in premenopausal women, and most cases have a secondary cause. Women with osteoporosis and no known secondary cause are said to have idiopathic osteoporosis (IOP). We aimed to estimate the proportion of premenopausal women seen in our referral center with IOP as opposed to secondary osteoporosis, to describe their clinical characteristics, to compare women with a low-trauma fracture history with those with low bone mineral density (BMD) alone, and to estimate the frequency of bisphosphonate use.

methodsWe reviewed medical records from all premenopausal women evaluated for osteoporosis or low BMD in our center during 2005. We included premenopausal women diagnosed on the basis of low-trauma fracture, low BMD or both (Z score < or= -2.0 or T score < or = -2.5), or both.

resultsAmong these patients (n = 61; mean age 37 +/- 8), 57 (93%) were Caucasian, 34 (57%) had a family history of osteoporosis, and 26 (43%) had used bisphosphonates. The most common secondary causes were amenorrhea (34%, n = 21), anorexia nervosa (16%, n = 10), and glucocorticoid exposure (13%, n = 8). After exclusion of secondary causes, 39% (24 of 61) of the entire group and 48% (14 of 29) of the fracture group were thought to have IOP. Women with a known secondary cause had lower BMD Z scores at the spine and hip than those with IOP. Women with low BMD and no fractures had shorter stature and weighed less than those with fractures, but overall differences between the groups were not statistically significant. Bisphosphonates had been prescribed for 38% (11 of 29) of women with a fracture history and 47% (15 of 32) of women with low BMD and no fractures.

conclusionsOur findings suggest that IOP is common among premenopausal women with osteoporosis or low BMD evaluated at a referral center. The smaller stature of women diagnosed only on the basis of BMD criteria raises the question of whether their areal BMD measurements are spuriously low because of smaller bone size. The high proportion of premenopausal women who had been prescribed oral bisphosphonates for low BMD measurements is of concern, as such women are likely to be at low short-term risk of fracture, and a more conservative approach to therapy is preferable in this group.

Indexed as

Absorptiometry, PhotonAdultAge FactorsAnthropometryBody HeightBody WeightBone DensityDiphosphonatesDrug Utilization ReviewFemaleFractures, BoneHipHospitals, UniversityHumansMiddle AgedNew York CityDiphosphonates

Identifiers

PMID19132880
PMCPMC3030453
OpenAlexW2094458983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.